Fibrinolysis has been recognized as an important cause of intraoperative bleeding during orthotopic liver transplantation (OLT). Several investigators have used prophylactic administration of aprotinin in patients to inhibit fibrinolysis and to decrease transfusion requirements, morbidity, and morta
Aprotinin in liver transplantation
β Scribed by Robert J. Porte; I. Quintus Molenaar
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 32 KB
- Volume
- 27
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The efficacy of tranexamic acid (TA) and aprotinin (AP) in reducing blood product requirements in orthotopic liver transplantation (OLT) was compared in a prospective, randomized and double-blind study. One hundred and twenty seven consecutive patients undergoing OLT were enrolled; TA was administer
Aprotinin is an antifibrinolytic drug that reduces blood loss during orthotopic liver transplantation (OLT). Case reports have suggested that aprotinin may be associated with an increased risk of thromboembolic complications. Recent studies in cardiac surgery also have suggested a higher risk of ren
Human liver transplantation has been possible since 1967. We report our experience in 32 adult patients who received liver transplants at the University of Pittsburgh over a 16-month period. Survival data, method utilized for patient selection, costs, and morbidity of the procedure are discussed. O
Prostaglandins have a broad spectrum of action. They are potent vasodilators, mediators of the inflammatory response, and have been found to decrease both humoral and cellular immune responses. Specifically in the liver, prostaglandins of the E series have been shown experimentally to have immunolog